Table 1. Patient and Organoid Characteristics.
| Name | Tissue Site | Tissue Studies | Organoid Studies |
Doubling Time | Prior Therapy | KPS | HGB (g/dL) |
ALB (g/dL) |
PSA (ng/dL) |
ALP (U/L) | LDH (U/L) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MSK-PCa1 | L2 Vetebral Body | WES of FFPE archival pelvic lymph node | WES, RNA-Seq, array-CGH | 3 days | ADT, bicalutamide | 90% | 13.1 | 4.8 | < 0.05 | 56 | 190 |
| MSK-PCa2 | Acetabulum | WES, RNA-Seq of matched tumor | WES, RNA-Seq, array-CGH | 3 days | ADT, bicalutamide | 60% | 10.4 | 4 | 8.71 | 134 | 175 |
| MSK-PCa3 | Retroperitoneal lymph node | n/a | WES, RNA-Seq, array-CGH | 1 week | ADT, bicalutamide, docetaxel, carboplatin | 80% | 10.7 | 4.5 | 0.08 | 112 | 154 |
| MSK-PCa4 | Pleural Effusion | n/a | WES, RNA-Seq, array-CGH | 2 weeks | ADT, bicalutamide, docetaxel | 50% | 9.4 | 2.8 | 0.94 | 69 | 222 |
| MSK-PCa5 | Circulating tumor cells | WES of FFPE archival pelvic lymph node | WES, RNA-Seq, array-CGH | 1 week | ADT, bicalutamide, abiraterone acetate | 60% | 8.4 | 3.9 | 180 | 2402 | 452 |
| MSK-PCa6 | Salvage prostatectomy | RNA-Seq of matched tumor | WES, RNA-Seq, array-CGH | 5 days | ADT, bicalutamide | 80% | 12.3 | 4 | <0.05 | 67 | 249 |
| MSK-PCa7 | Retroperitoneal lymph node | WES, RNA-Seq of matched tumor | WES, RNA-Seq, array-CGH | 3 weeks | None | 90% | 16.2 | 4.7 | 3.87 | 199 | 114 |